<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/archiving/3.0/archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Immunol</journal-id><journal-id journal-id-type="publisher-id">eji</journal-id><journal-title-group><journal-title>European Journal of Immunology</journal-title></journal-title-group><issn pub-type="ppub">0014-2980</issn><issn pub-type="epub">1521-4141</issn><publisher><publisher-name>WILEY-VCH Verlag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1002/eji.200738106</article-id><article-categories><subj-group subj-group-type="heading"><subject>Leukocyte signaling</subject></subj-group></article-categories><title-group><article-title>Engagement of the EP<sub>2</sub> prostanoid receptor closes the K<sup>+</sup> channel K<sub>Ca</sub>3.1 in human lung mast cells and attenuates their migration</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Duffy</surname><given-names>S Mark</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cruse</surname><given-names>Glenn</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cockerill</surname><given-names>Sarah L</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brightling</surname><given-names>Chris E</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bradding</surname><given-names>Peter</given-names></name></contrib></contrib-group><aff><institution>The Department of Infection, Immunity and Inflammation, Institute for Lung Health, University of Leicester</institution><addr-line>UK</addr-line></aff><author-notes><corresp id="cor1">Full correspondence: Professor Peter Bradding, Department of Respiratory Medicine, Glenfield Hospital, Groby Rd, Leicester LE3 9QP, UK Fax: +44-116-2502787 e-mail: <email>pbradding@hotmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>9</month><year>2008</year></pub-date><volume>38</volume><issue>9</issue><fpage>2548</fpage><lpage>2556</lpage><history><date date-type="received"><day>20</day><month>12</month><year>2007</year></date><date date-type="rev-recd"><day>04</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>03</day><month>7</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 WILEY-VCH Verlag GmbH &#x00026; Co. KGaA, Weinheim</copyright-statement><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.</license-p></license></permissions><abstract><p>Human lung mast cells (HLMC) express the Ca<sup>2+</sup>-activated K<sup>+</sup> channel K<sub>Ca</sub>3.1, which plays a crucial role in their migration to a variety of diverse chemotactic stimuli. K<sub>Ca</sub>3.1 activation is attenuated by the &#x003b2;<sub>2</sub>-adrenoceptor and the adenosine A<sub>2A</sub> receptor through a G<sub>s</sub>-coupled mechanism independent of cyclic AMP. Prostaglandin E<sub>2</sub> promotes degranulation and migration of mouse bone marrow-derived mast cells through the G<sub>i</sub>-coupled EP<sub>3</sub> prostanoid receptor, and induces LTC<sub>4</sub> and cytokine secretion from human cord blood-derived mast cells. However, PGE<sub>2</sub> binding to the G<sub>s</sub>-coupled EP<sub>2</sub> receptor on HLMC inhibits their degranulation. We show that EP<sub>2</sub> receptor engagement closes K<sub>Ca</sub>3.1 in HLMC. The EP<sub>2</sub> receptor-specific agonist butaprost was more potent than PGE<sub>2</sub> in this respect, and the effects of both agonists were reversed by the EP<sub>2</sub> receptor antagonist AH6809. Butaprost markedly inhibited HLMC migration induced by chemokine-rich airway smooth muscle-conditioned media. Interestingly, PGE<sub>2</sub> alone was chemotactic for HLMC at high concentrations (1 &#x000b5;M), but was a more potent chemoattractant for HLMC following EP<sub>2</sub> receptor blockade. Therefore, the G<sub>s</sub>-coupled EP<sub>2</sub> receptor closes K<sub>Ca</sub>3.1 in HLMC and attenuates both chemokine- and PGE<sub>2</sub>-dependent HLMC migration. EP<sub>2</sub> receptor agonists with K<sub>Ca</sub>3.1 modulating function may be useful for the treatment of mast cell-mediated disease.</p></abstract><kwd-group><kwd>Chemotaxis</kwd><kwd>Ion channel</kwd><kwd>K<sub>Ca</sub>3.1</kwd><kwd>Mast cell</kwd><kwd>Prostaglandin E<sub>2</sub></kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>Mast cells are tissue-dwelling cells derived from bone marrow progenitors. They are present in all organs throughout the human body, both at mucosal surfaces and within connective tissues. Mast cells play a major role in tissue homeostasis, host defence and the pathophysiology of many diverse diseases <xref ref-type="bibr" rid="b1">1</xref>. These include pulmonary fibrosis, rheumatoid disease and atherosclerosis, but they are most commonly associated with allergic disease due to their activation by allergen <xref ref-type="bibr" rid="b2">2</xref>. In many diseases mast cells re-locate to specific compartments within tissue. This is typified in asthma where mast cells migrate into the airway epithelium <xref ref-type="bibr" rid="b3">3</xref>, airway smooth muscle (ASM) <xref ref-type="bibr" rid="b4">4</xref> and submucosal glands <xref ref-type="bibr" rid="b5">5</xref>. This places activated mast cells in direct contact with these dysfunctional airway elements, allowing the specific delivery of detrimental cell&#x02013;cell signals. Drugs that inhibit this tissue relocation by preventing mast cell migration may prove particularly effective in the treatment of mast cell-mediated disease.</p><p>Human mast cells express the intermediate conductance Ca<sup>2+</sup>-activated K<sup>+</sup> channel K<sub>Ca</sub>3.1, which plays a critical role in their migration to diverse chemotactic stimuli <xref ref-type="bibr" rid="b6">6</xref>, and to a lesser extent in their degranulation <xref ref-type="bibr" rid="b7">7</xref>, <xref ref-type="bibr" rid="b8">8</xref>. Drugs that directly block this channel or which close it indirectly therefore have potential as novel therapies for mast cell-dependent disease. K<sub>Ca</sub>3.1 in human lung mast cells (HLMC) is closed by both salbutamol and adenosine <italic>via</italic> the &#x003b2;<sub>2</sub>-adrenoceptor and A<sub>2A</sub> adenosine receptors, respectively <xref ref-type="bibr" rid="b9">9</xref>, <xref ref-type="bibr" rid="b10">10</xref>, which are both G<sub>s</sub>-coupled G protein-coupled receptors (GPCR). In keeping with a critical role for K<sub>Ca</sub>3.1 in HLMC migration, adenosine also inhibits HLMC chemotaxis <italic>via</italic> the A<sub>2A</sub> receptor <xref ref-type="bibr" rid="b10">10</xref>.</p><p>PGE<sub>2</sub> is a prostanoid with four specific GPCR, designated EP<sub>1&#x02013;4</sub>. EP<sub>2</sub> and EP<sub>4</sub> couple to G<sub>s</sub>, EP<sub>3</sub> couples predominantly to G<sub>i</sub> although two isoforms also couple to G<sub>s</sub>, while EP<sub>1</sub> receptors mobilise intracellular Ca<sup>2+</sup>, probably through G<sub>q</sub><xref ref-type="bibr" rid="b11">11</xref>. PGE<sub>2</sub> therefore has diverse biological activities depending on the receptors it interacts with and the cells expressing them. With respect to mast cells, mouse mast cells express the EP<sub>3</sub> receptor whose activation induces both degranulation and chemotaxis <xref ref-type="bibr" rid="b12">12</xref>, <xref ref-type="bibr" rid="b13">13</xref>. Human cord blood-derived mast cells, express both EP<sub>2</sub> and EP<sub>3</sub> receptors. In these cells, PGE<sub>2</sub> enhances degranulation and PGD<sub>2</sub> production in cells primed by IL-4, an effect mediated through the EP<sub>3</sub> receptor. However, following Fc&#x0025b;RI-dependent activation PGE<sub>2</sub> inhibits human cord blood-derived mast cell LTC<sub>4</sub>, PGD<sub>2</sub>, IL-5 and TNF-&#x003b1; production <italic>via</italic> the EP<sub>2</sub> receptor but has no effect on degranulation <xref ref-type="bibr" rid="b14">14</xref>. In contrast, several studies have shown that PGE<sub>2</sub> consistently inhibits degranulation and eicosanoid production by HLMC, an effect mediated <italic>via</italic> the EP<sub>2</sub> receptor <xref ref-type="bibr" rid="b15">15</xref>&#x02013;<xref ref-type="bibr" rid="b17">17</xref>. This receptor also appears to dominate PGE<sub>2</sub>-dependent signalling on mast cells within the human asthmatic lung as PGE<sub>2</sub> markedly attenuates both the early and late phase airway response to allergen challenge <xref ref-type="bibr" rid="b18">18</xref>.</p><p>Since K<sub>Ca</sub>3.1 in HLMC is closed by G<sub>s</sub>-coupled &#x003b2;<sub>2</sub>-adrenoceptors and A<sub>2A</sub> adenosine receptors, we hypothesised that activation of the G<sub>s</sub>-coupled EP<sub>2</sub> receptor would also close K<sub>Ca</sub>3.1 in these cells. Furthermore, if PGE<sub>2</sub> was to close K<sub>Ca</sub>3.1, then it should inhibit HLMC chemotaxis. To test this hypothesis we have used the patch-clamp technique to investigate the effects of PGE<sub>2</sub> on HLMC ion channel function, and investigated the effect of PGE<sub>2</sub> on HLMC migration induced by asthmatic ASM-conditioned medium.</p></sec><sec><title>Results</title><sec><title>PGE<sub>2</sub> alone does not open K<sub>Ca</sub>3.1</title><p>We initially examined whether PGE<sub>2</sub> opens K<sub>Ca</sub>3.1 in HLMC under resting baseline conditions. HLMC are typically electrically silent at rest and it is possible that PGE<sub>2</sub> could open either K<sub>Ca</sub>3.1 or another channel as reported previously for adenosine <xref ref-type="bibr" rid="b10">10</xref>. No significant change in current amplitude was observed in seven cells following the addition of 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> (current changed from 1.22&#x000b1;0.54 to 1.42&#x000b1;0.85 pA at +40 mV; <italic>p</italic>=0.678).</p></sec><sec><title>PGE<sub>2</sub> closes K<sub>Ca</sub>3.1 in the presence of the K<sub>Ca</sub>3.1 opener 1-EBIO</title><p>We then examined whether PGE<sub>2</sub> closes K<sub>Ca</sub>3.1. Because PGE<sub>2</sub> might potentially inhibit many IgE-dependent cell activation pathways that could reduce cytosolic-free Ca<sup>2+</sup>, and thus reduce K<sub>Ca</sub>3.1 activity indirectly, we concentrated on studying the effects of PGE<sub>2</sub> on K<sub>Ca</sub>3.1 currents that were induced by the K<sub>Ca</sub>3.1 opener 1-EBIO <xref ref-type="bibr" rid="b8">8</xref>&#x02013;<xref ref-type="bibr" rid="b10">10</xref>. This compound opens K<sub>Ca</sub>3.1 with a half-maximal value of about 30 &#x000b5;M for heterologously expressed K<sub>Ca</sub>3.1, with a maximal effect at about 300 &#x000b5;M <xref ref-type="bibr" rid="b19">19</xref>. 1-EBIO is specific for K<sub>Ca</sub>3.1 in HLMC and opens it by enhancing the channels sensitivity to [Ca<sup>2+</sup>]<sub>i</sub><xref ref-type="bibr" rid="b19">19</xref>. Thus at 100 &#x000b5;M EBIO, maximal K<sup>+</sup> currents are achieved in the presence of 100 nM free Ca<sup>2+</sup>, which is below the resting [Ca<sup>2+</sup>]<sub>i</sub> of most cell types including HLMC <xref ref-type="bibr" rid="b8">8</xref>.</p><p>In cells in which K<sub>Ca</sub>3.1 had been activated by 1-EBIO, addition of PGE<sub>2</sub> (10<sup>&#x02212;8</sup>&#x02013;10<sup>&#x02212;5</sup> M) produced a rapid (within 30 s) dose-responsive inhibition of channel activity with an associated positive shift in membrane potential (<xref ref-type="fig" rid="fig01">Fig. 1A&#x02013;E</xref>). PGE<sub>2</sub> 10<sup>&#x02212;5</sup> M suppressed the K<sub>Ca</sub>3.1 current in &#x0003e;90% of cells (<xref ref-type="fig" rid="fig01">Fig. 1B</xref>). Thus, addition of 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> reduced K<sub>Ca</sub>3.1 membrane current at +40 mV from 155.4&#x000b1;20.9 to 92.6&#x000b1;13.7 pA (<italic>p</italic>=0.0001, <italic>n</italic>=22 cells)(<xref ref-type="fig" rid="fig01">Fig. 1B</xref>), with a corresponding shift in reversal potential (Vm) from &#x02212;69.5&#x000b1;2.8 to &#x02212;56.3&#x000b1;3.9 mV (<italic>p</italic>=0.0004) (<xref ref-type="fig" rid="fig01">Fig. 1C</xref>). Half maximal suppression (IC<sub>50</sub>) of K<sub>Ca</sub>3.1 by PGE<sub>2</sub> occurred at approximately 4.0&#x000d7;10<sup>&#x02212;7</sup> M (calculated from six cells). Importantly, the effect of PGE<sub>2</sub> was partially reversed within 1 min by removing it from the recording solution (current post PGE<sub>2</sub> 49.6&#x000b1;20.8 pA, post wash 103.4&#x000b1;34.5 pA, <italic>p</italic>=0.046; Vm post PGE<sub>2</sub> &#x02212;44.1&#x000b1;11.7 mV, post wash &#x02212;72.1&#x000b1;6.81 mV, <italic>p</italic>=0.028, <italic>n</italic>=5) (<xref ref-type="fig" rid="fig01">Fig. 1D and E</xref>), indicating that non-specific &#x0201c;rundown&#x0201d; was not responsible for the effects seen.</p><fig id="fig01" position="float"><label>Figure 1</label><caption><p>PGE<sub>2</sub> closes K<sub>Ca</sub>3.1 in HLMC in a consistent and reversible manner. (A) Current&#x02013;voltage curve demonstrating suppression of a 1-EBIO-induced K<sub>Ca</sub>3.1 current by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> and partial reversal of the effect following removal of PGE<sub>2</sub> (wash). (B) Suppression of K<sub>Ca</sub>3.1 current measured at +40 mV by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> (<italic>n</italic>=22 cells). (C) Shift in whole-cell current reversal potential (Vm) by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> (<italic>n</italic>=22 cells). (D) K<sub>Ca</sub>3.1 current measured at +40 mV after addition of 1-EBIO, suppression by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> and then reversibility of suppression following removal of PGE<sub>2</sub> (wash) (<italic>n</italic>=5 cells). (E) Whole-cell current reversal potential (Vm) after the addition of 1-EBIO, a depolarising positive shift in response to 10<sup>&#x02212;5</sup> M PGE<sub>2</sub>, and then reversibility following removal of PGE<sub>2</sub> (wash) (<italic>n</italic>=5 cells).</p></caption><graphic xlink:href="eji0038-2548-f1"/></fig></sec><sec><title>K<sub>Ca</sub>3.1 modulation by PGE<sub>2</sub> is mediated <italic>via</italic> EP<sub>2</sub> receptors</title><p>To examine whether the effects of PGE<sub>2</sub> were mediated via EP<sub>2</sub> prostanoid receptors we examined the effects of EP<sub>2</sub> receptor agonists/antagonists. First, we examined the effects of the selective EP<sub>2</sub> receptor agonist butaprost. Butaprost mimicked the effects of native PGE<sub>2</sub> in a dose-dependent manner (<xref ref-type="fig" rid="fig02">Fig. 2A&#x02013;D</xref>). At a concentration of 10<sup>&#x02212;5</sup> M, butaprost reduced the K<sub>Ca</sub>3.1 current from 146.0&#x000b1;18.3 pA to 61.2&#x000b1;6.1 pA (<italic>p</italic>=0.00006, <italic>n</italic>=20) (<xref ref-type="fig" rid="fig02">Fig. 2B</xref>) with a corresponding shift in reversal from &#x02212;67.5&#x000b1;1.4 to &#x02212;54.4&#x000b1;3.2 mV (<italic>p</italic>=0.00006) (<xref ref-type="fig" rid="fig02">Fig. 2C</xref>). Half maximal suppression (IC<sub>50</sub>) of K<sub>Ca</sub>3.1 by butaprost occurred at approximately 2.1&#x000d7;10<sup>&#x02212;7</sup> M (<italic>n</italic>=6 cells) (<xref ref-type="fig" rid="fig02">Fig. 2D</xref>).</p><fig id="fig02" position="float"><label>Figure 2</label><caption><p>The EP<sub>2</sub> receptor agonist butaprost closes K<sub>Ca</sub>3.1 in HLMC. (A) Current&#x02013;voltage curve demonstrating suppression of a 1-EBIO-induced K<sub>Ca</sub>3.1 current by 10<sup>&#x02212;5</sup> butaprost. (B) Suppression of K<sub>Ca</sub>3.1 current measured at +40 mV by 10<sup>&#x02212;5</sup> M butaprost (<italic>n</italic>=20 cells). (C) Shift in whole-cell current reversal potential (Vm) by 10<sup>&#x02212;5</sup> M butaprost (<italic>n</italic>=20 cells). (D) Concentration&#x02013;response curves for K<sub>Ca</sub>3.1 suppression by PGE<sub>2</sub> and the EP<sub>2</sub> agonist butaprost (mean&#x000b1;SEM of five cells for each).</p></caption><graphic xlink:href="eji0038-2548-f2"/></fig><p>The suppression of K<sub>Ca</sub>3.1 by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> was partially reversed by the competitive EP<sub>1</sub> and EP<sub>2</sub> receptor antagonist AH6809 (<xref ref-type="fig" rid="fig03">Fig. 3A&#x02013;C</xref>). Thus, in experiments studying AH6809 at a concentration of 10<sup>&#x02212;5</sup> M, current at +40 mV was 112&#x000b1;14.3 pA post PGE<sub>2</sub>, increasing to 160.9&#x000b1;23.2 pA post AH6809 (<italic>p</italic>=0.011, <italic>n</italic>=10 cells) (<xref ref-type="fig" rid="fig03">Fig. 3B</xref>). There was however no significant shift in reversal potential in these experiments explained by the fact that significant K<sub>Ca</sub>3.1 currents remained following PGE<sub>2</sub> application (Vm post PGE<sub>2</sub> &#x02212;60.9&#x000b1;2.1 mV, post AH6809 &#x02212;63.6&#x000b1;1.8 mV, <italic>p</italic>=0.17) (<xref ref-type="fig" rid="fig03">Fig. 3C</xref>). We also examined the effect of AH6809 on the selective EP<sub>2</sub> agonist butaprost. The suppression of K<sub>Ca</sub>3.1 by 10<sup>&#x02212;5</sup> M butaprost was also partially reversed by 10<sup>&#x02212;5</sup> M AH6809 (<xref ref-type="fig" rid="fig03">Fig. 3D&#x02013;F</xref>). Current at +40 mV was 58.5&#x000b1;8.3 pA post butaprost, increasing to 111.6&#x000b1;15.9 pA post AH6809 (<italic>p</italic>=0.0004, <italic>n</italic>=12) (<xref ref-type="fig" rid="fig03">Fig. 3E</xref>). There was also a significant shift in reversal potential (Vm post butaprost &#x02212;48.1&#x000b1;5.8 mV, post AH6809 &#x02212;61.0&#x000b1;3.7 mV, <italic>p</italic>=0.0004) (<xref ref-type="fig" rid="fig03">Fig. 3F</xref>). In the presence of AH6809, PGE<sub>2</sub> had no effect on K<sub>Ca</sub>3.1 currents that had been induced by 1-EBIO (current at +40 mV 67.0&#x000b1;17.2 pA post 1-EBIO, 66.2&#x000b1;15.7 post AH6809, 62.7&#x000b1;13.7 pA post PGE<sub>2</sub>, <italic>n</italic>=7)(<xref ref-type="fig" rid="fig04">Fig. 4A</xref>). Similarly, K<sub>Ca</sub>3.1 currents did not appear in resting cells to which AH6809 was added prior to PGE<sub>2</sub> (current 6.9&#x000b1;0.9 pA at baseline, 5.8&#x000b1;0.6 pA post AH6809, 6.3&#x000b1;1.1 pA post PGE<sub>2</sub>, <italic>n</italic>=6) (<xref ref-type="fig" rid="fig04">Fig. 4B</xref>). The EP<sub>1</sub> and EP<sub>3</sub> receptor agonist 17-phenyl trinor PGE<sub>2</sub> did not close K<sub>Ca</sub>3.1 after activation with 1-EBIO (current at +40 mV post 1-EBIO 128.3&#x000b1;94.9 pA, post 17-phenyl trinor PGE<sub>2</sub> 127.8&#x000b1;90.4 pA, <italic>p</italic>=0.9567, <italic>n</italic>=6) and did not open K<sub>Ca</sub>3.1 in resting cells (baseline current at +40 mV 5.70&#x000b1;0.88 pA, current post 17-phenyl trinor PGE<sub>2</sub> 5.36&#x000b1;0.949 pA, <italic>p</italic>=0.202, <italic>n</italic>=5). These results exclude a role for EP<sub>1</sub>, EP<sub>3</sub> or EP<sub>4</sub> receptors in K<sub>Ca</sub>3.1 modulation. Taking the data together, it can be concluded that suppression of K<sub>Ca</sub>3.1 by PGE<sub>2</sub> is mediated by the EP<sub>2</sub> receptor.</p><fig id="fig03" position="float"><label>Figure 3</label><caption><p>The effect of the EP<sub>1</sub>/<sub>2</sub> receptor antagonist AH6809 on PGE<sub>2</sub>- and butaprost -dependent closure of K<sub>Ca</sub>3.1. (A) Current&#x02013;voltage curve demonstrating reversibility of K<sub>Ca</sub>3.1 suppression by PGE<sub>2</sub> following administration of the EP<sub>1/2</sub> receptor antagonist AH6809. (B) K<sub>Ca</sub>3.1 current measured at +40 mV after addition of 1-EBIO, suppression by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> and then reversibility of suppression following addition of AH6809 (<italic>n</italic>=10 cells). (C) Whole-cell current reversal potential (Vm) after the addition of 1-EBIO, a depolarising positive shift in response to 10<sup>&#x02212;5</sup> M PGE<sub>2</sub>, and then following addition AH6809 (<italic>n</italic>=10 cells). (D) Current&#x02013;voltage curve demonstrating reversibility of K<sub>Ca</sub>3.1 suppression by butaprost following administration of AH6809. (E) K<sub>Ca</sub>3.1 current measured at +40 mV after addition of 1-EBIO, suppression by 10<sup>&#x02212;5</sup> M butaprost and then reversibility of suppression following addition of AH6809 (<italic>n</italic>=12 cells). (F) Whole-cell current reversal potential (Vm) after the addition of 1-EBIO, a depolarising positive shift in response to 10<sup>&#x02212;5</sup> M PGE<sub>2</sub>, and then reversibility following addition AH6809 (<italic>n</italic>=12 cells).</p></caption><graphic xlink:href="eji0038-2548-f3"/></fig><fig id="fig04" position="float"><label>Figure 4</label><caption><p>PGE<sub>2</sub> is ineffective in the presence of the AH6809. (A) K<sub>Ca</sub>3.1 current measured at +40 mV after addition of 1-EBIO, stability following addition of AH6809, and failure to suppress following subsequent addition of 10<sup>&#x02212;5</sup> M PGE<sub>2</sub>. (B) K<sub>Ca</sub>3.1 current measured at +40 mV in resting cells, after addition of AH6809, and then following subsequent addition of 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> showing failure of K<sub>Ca</sub>3.1 to open.</p></caption><graphic xlink:href="eji0038-2548-f4"/></fig></sec><sec><title>PGE<sub>2</sub> closes K<sub>Ca</sub>3.1 following IgE-dependent activation</title><p>Lastly, we confirmed whether PGE<sub>2</sub>-dependent regulation of K<sub>Ca</sub>3.1 was relevant to K<sub>Ca</sub>3.1 channels that had been opened by anti-IgE-dependent activation. Anti-IgE (1:1000 dilution) opened K<sub>Ca</sub>3.1 in 5/5 cells tested (baseline current at +40 mV 5.8&#x000b1;1.3 pA, baseline Vm &#x02212;17.8&#x000b1;3.2 mV; post anti-IgE current 54.2&#x000b1;7.6 pA, Vm &#x02212;62.4&#x000b1;3.0 mV). PGE<sub>2</sub> (10<sup>&#x02212;5</sup> M) suppressed the current to 34.3&#x000b1;4.9 pA post PGE<sub>2</sub>, <italic>p</italic>=0.005) (<xref ref-type="fig" rid="fig05">Fig. 5A and B</xref>) and produced an associated positive shift in Vm to &#x02212;52.2&#x000b1;4.1 mV, <italic>p</italic>=0.051) (<xref ref-type="fig" rid="fig05">Fig. 5C</xref>). This suppressive effect of PGE<sub>2</sub> was partially reversed by AH6809 (current 48.3&#x000b1;6.9 pA, <italic>p</italic>=0.011; Vm &#x02212;66.6&#x000b1;4.0 mV, <italic>p</italic>=0.041) (<xref ref-type="fig" rid="fig05">Fig. 5A and C</xref>).</p><fig id="fig05" position="float"><label>Figure 5</label><caption><p>The effect of 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> on K<sub>Ca</sub>3.1 currents elicited by anti-IgE-dependent mast cell activation. (A) A representative HLMC demonstrating the development of a K<sub>Ca</sub>3.1 current following anti-IgE-dependent activation, suppression of this by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub>, and reversal of the PGE<sub>2</sub>-induced suppression by the EP<sub>1/2</sub> receptor antagonist AH6809. (B) K<sub>Ca</sub>3.1 current measured at +40 mV after addition of anti-IgE, suppression by 10<sup>&#x02212;5</sup> M PGE<sub>2</sub> and then reversibility of suppression following addition of AH6809 (<italic>n</italic>=5 cells). (C) Whole-cell current reversal potential (Vm) after the addition of anti-IgE, a depolarising positive shift in response to 10<sup>&#x02212;5</sup> M PGE<sub>2</sub>, and then reversibility following addition AH6809 (<italic>n</italic>=5 cells).</p></caption><graphic xlink:href="eji0038-2548-f5"/></fig></sec><sec><title>PGE<sub>2</sub> suppresses HLMC migration through the EP<sub>2</sub> receptor</title><p>Conditioned medium from asthmatic ASM, which has been activated with TNF&#x003b1;, IFN&#x003b3; and IL-1&#x003b2;, mediates HLMC chemotaxis predominantly <italic>via</italic> the CXCL10/CXCR3 pathway with additional contributions from ligands for CXCR1 and CXCR3 <xref ref-type="bibr" rid="b20">20</xref>. Inhibition of K<sub>Ca</sub>3.1 by channel blockers markedly suppresses this HLMC chemotaxis <xref ref-type="bibr" rid="b6">6</xref>, as do molecules that close K<sub>Ca</sub>3.1 such as adenosine <xref ref-type="bibr" rid="b10">10</xref>. Migration of HLMC using conditioned medium from asthmatic airway smooth muscle was 2.8&#x000b1;0.9 fold that of medium control (<italic>n</italic>=4, <italic>p</italic>=0.046) (<xref ref-type="fig" rid="fig06">Fig. 6A</xref>) and this was not inhibited significantly by PGE<sub>2</sub> (<xref ref-type="fig" rid="fig06">Fig. 6B</xref>). However, the selective EP<sub>2</sub> agonist butaprost produced marked inhibition of HLMC migration to ASM-conditioned medium (<xref ref-type="fig" rid="fig06">Fig. 6B</xref>). Interestingly, PGE<sub>2</sub> was chemotactic on its own, but much less potent than in mouse bone marrow-derived mast cells <xref ref-type="bibr" rid="b13">13</xref> (<xref ref-type="fig" rid="fig06">Fig. 6C</xref>). This HLMC chemotactic activity of PGE<sub>2</sub> was markedly increased in the presence of EP<sub>1/2</sub> blockade by AH6809 10<sup>&#x02212;5</sup> M (<xref ref-type="fig" rid="fig06">Fig. 6D</xref>). HLMC migration to both ASM-conditioned medium and PGE<sub>2</sub> itself is therefore attenuated by the EP<sub>2</sub> receptor.</p><fig id="fig06" position="float"><label>Figure 6</label><caption><p>Inhibition of HLMC chemotaxis through EP<sub>2</sub> receptor activation. (A) HLMC migration using conditioned medium from asthmatic airway smooth muscle as the chemotactic stimulus. (B) HLMC migration is attenuated significantly by butaprost (n=4) but not PGE<sub>2</sub> (<italic>n</italic>=3) in the presence of ASM-conditioned medium. <sup>*</sup><italic>p</italic>&#x0003c;0.05 compared with control (no PGE<sub>2</sub> or butaprost). (C) PGE<sub>2</sub> is chemotactic when present in isolation. <sup>*</sup><italic>p</italic>&#x0003c;0.05 compared to control (no PGE<sub>2</sub>), <italic>n</italic>=4. (D) PGE<sub>2</sub>-dependent chemotaxis is enhanced in the presence of the EP<sub>1/2</sub> receptor antagonist AH6809 (10<sup>&#x02212;5</sup> M). <sup>*</sup><italic>p</italic>&#x0003c;0.05 compared to control (no AH6809), <italic>n</italic>=4.</p></caption><graphic xlink:href="eji0038-2548-f6"/></fig></sec><sec><title>PGE<sub>2</sub> attenuates histamine release from cultured HLMC</title><p>PGE<sub>2</sub> inhibits the degranulation of HLMC freshly isolated from lung tissue. Because the cells used in this study were cultured in stem cell factor (SCF), IL-6 and IL-10, we investigated whether PGE<sub>2</sub> also inhibits release from these HLMC. In keeping with observations in freshly isolated HLMC, PGE<sub>2</sub> inhibited histamine release dose dependently over the concentration range 10<sup>&#x02212;9</sup>&#x02013;10<sup>&#x02212;6</sup> M (control mean&#x000b1;s.e.m. net histamine release 19.8&#x000b1;3.7% versus 7.5&#x000b1;3.3% with 10<sup>&#x02212;6</sup> PGE<sub>2</sub>, <italic>n</italic>=4 donors, <italic>p</italic>=0.046).</p></sec><sec><title>K<sub>Ca</sub>3.1 is not modulated by G<sub>i</sub> or G<sub>q</sub>-coupled receptors</title><p>We have now identified three distinct G<sub>s</sub>-coupled receptors that close K<sub>Ca</sub>3.1 in HLMC when exposed to the relevant ligands, and in the case of the &#x003b2;<sub>2</sub>-adrenoceptor, the inverse agonist ICI 118551 opens the channel <xref ref-type="bibr" rid="b9">9</xref>. In contrast, the G<sub>i</sub>-coupled CXCR3 receptor does not couple directly to K<sub>Ca</sub>3.1 <xref ref-type="bibr" rid="b6">6</xref>. We have therefore investigated further G<sub>i</sub> and G<sub>q</sub> agonists known to have biological effects on HLMC. Platelet activating factor (PAF, 10<sup>&#x02212;7</sup> M) (G<sub>i</sub>), lysophosphatidic acid (LPA, 10<sup>&#x02212;5</sup> M) (G<sub>q,12/13,i</sub>) and UTP (10<sup>&#x02212;4</sup> M)(G<sub>q</sub>) did not open K<sub>Ca</sub>3.1 in resting HLMC (<italic>n</italic>=&#x02265;6 cells for each agonist) and did not close K<sub>Ca</sub>3.1 that had been opened by 1-EBIO (<italic>n</italic>=&#x02265;5 cells for each agonist)(data not shown).</p></sec></sec><sec><title>Discussion</title><p>In this study we have examined the effects of EP<sub>2</sub> receptor activation on K<sub>Ca</sub>3.1 ion channel function in HLMC. In keeping with the known effects of the &#x003b2;<sub>2</sub>-adrenoceptor and A<sub>2A</sub> adenosine receptor <xref ref-type="bibr" rid="b9">9</xref>, <xref ref-type="bibr" rid="b10">10</xref>, the G<sub>s</sub>-coupled EP<sub>2</sub> receptor also closes this channel reversibly. Consistent with this effect on the channel, EP<sub>2</sub> receptor activation attenuates HLMC migration, and in consequence masks the potential chemotactic activity of PGE<sub>2</sub> on HLMC, which is particularly evident when the EP<sub>2</sub> receptor is blocked pharmacologically.</p><p>PGE<sub>2</sub> closed K<sub>Ca</sub>3.1 reversibly following IgE-dependent mast cell activation demonstrating physiological relevance. PGE<sub>2</sub> also closed K<sub>Ca</sub>3.1 channels that had been activated by the K<sub>Ca</sub>3.1 opener 1-EBIO. The inhibition of K<sub>Ca</sub>3.1 by PGE<sub>2</sub> was reversed both by removing it from the recording solution, and by the addition of the competitive EP<sub>1</sub> and EP<sub>2</sub> receptor antagonist AH6809 indicating a receptor-mediated mechanism. Since the effects of PGE<sub>2</sub> were mimicked by the specific EP<sub>2</sub> receptor agonist butaprost but not the EP<sub>1</sub> agonist 17-phenyl trinor PGE<sub>2</sub>, and no effects of native PGE<sub>2</sub> were seen in the presence of the EP<sub>1/2</sub> receptor antagonist AH6809, we have firm evidence that the suppression of K<sub>Ca</sub>3.1 by PGE<sub>2</sub> is mediated via the EP<sub>2</sub> receptor.</p><p>Because 1-EBIO opens K<sub>Ca</sub>3.1 directly in resting cells by increasing its affinity for Ca<sup>2+</sup><xref ref-type="bibr" rid="b19">19</xref>, it suggests that there is tight coupling between the EP<sub>2</sub> receptor and the channel rather than modulation of intracellular signalling pathways. The ability of PGE<sub>2</sub> to close K<sub>Ca</sub>3.1 is in keeping with our previous observations that this channel is closed by G<sub>s</sub>-coupled &#x003b2;<sub>2</sub>-adrenoceptors <xref ref-type="bibr" rid="b9">9</xref> and G<sub>s</sub>-coupled adenosine A<sub>2A</sub> receptors <xref ref-type="bibr" rid="b10">10</xref>. These effects on K<sub>Ca</sub>3.1 are not mimicked by cAMP analogues or the activator of adenylate cyclase forskolin <xref ref-type="bibr" rid="b9">9</xref>, and considering they are seen in whole-cell configuration of the patch-clamp technique, indicate that the most likely mechanism of action is membrane-delimited involving the G<sub>&#x003b1;s</sub> or &#x003b2;&#x003b3; subunits of these GPCR. This view is further supported by the observation that the &#x003b2;<sub>2</sub>-adrenoceptor inverse agonist ICI-118551 actually opens K<sub>Ca</sub>3.1 <xref ref-type="bibr" rid="b9">9</xref>, but G<sub>i</sub> agonists such as CXCL10 and PAF, which lower intracellular cAMP, do not directly activate this channel <xref ref-type="bibr" rid="b6">6</xref>.</p><p>The ability of GPCR to modify K<sub>Ca</sub>3.1 appears to be limited to G<sub>s</sub>-coupled receptors as we have not found any evidence that G<sub>i</sub>, G<sub>q</sub>, or G<sub>12/13</sub>-coupled receptors modify K<sub>Ca</sub>3.1 activity. In particular blockade of EP<sub>1</sub> and EP<sub>2</sub> in this study did not uncover any G<sub>i</sub>-coupled EP<sub>3</sub> effects, and GPCR agonists active on human mast cells such as CXCL10 (G<sub>&#x003b1;i</sub>) <xref ref-type="bibr" rid="b6">6</xref>, PAF (G<sub>i</sub>), LPA (G<sub>q, &#x02212;12/13 and i</sub>), and UTP (G<sub>&#x003b1;q</sub> P2Y2 receptor) do not open or close K<sub>Ca</sub>3.1 in HLMC. It is well established using cell attached, inside-out and outside patch-clamp recording that most classes of GPCR including G<sub>&#x003b1;s</sub> couple directly to ion channels through membrane-delimited mechanisms <xref ref-type="bibr" rid="b21">21</xref>, <xref ref-type="bibr" rid="b22">22</xref>. This may lead to either channel opening or channel closing depending on the channel and receptor, and may utilise either the G<sub>&#x003b1;</sub> component or specific combinations of &#x003b2;&#x003b3; subunits <xref ref-type="bibr" rid="b21">21</xref>, <xref ref-type="bibr" rid="b22">22</xref>. A further level of specificity between receptor and channel is likely to be achieved by the close approximation of these proteins in tight membrane-restricted signalling complexes. For example, the &#x003b2;<sub>2</sub> adrenoceptor that can modify both K<sub>Ca</sub>1.1 and voltage-gated Ca<sup>2+</sup> channel gating is associated with these two channels in a macromolecular complex held together by A-kinase-anchoring proteins <xref ref-type="bibr" rid="b23">23</xref>. It is therefore interesting to speculate that K<sub>Ca</sub>3.1 also localises with the various G<sub>&#x003b1;s</sub> receptors that modify its function. This and the exact mechanism by which G<sub>&#x003b1;s</sub> modifies K<sub>Ca</sub>3.1 function will be an important area for future research.</p><p>Several molecules that attenuate HLMC secretion including PGE<sub>2</sub>, adenosine and &#x003b2;<sub>2</sub>-adrenoceptor agonists increase intracellular cAMP <xref ref-type="bibr" rid="b24">24</xref>. The generally held view is that this increase in intracellular cAMP couples to inhibition of secretion, supported by the observation that cAMP analogues and non-specific inhibitors of adenylate cyclase can also attenuate secretion from HLMC <xref ref-type="bibr" rid="b24">24</xref>. However, no mechanism has been identified in mast cells that explains how increases in cAMP inhibit the secretory pathway, and the exclusive role of cAMP in the inhibition of other systems such as smooth muscle relaxation has been challenged <xref ref-type="bibr" rid="b25">25</xref>. Opening of K<sub>Ca</sub>3.1 enhances IgE-dependent Ca<sup>2+</sup> influx and degranulation to a submaximal stimulus <xref ref-type="bibr" rid="b8">8</xref>, and its blockade by charybdotoxin attenuates this <xref ref-type="bibr" rid="b7">7</xref>. Thus, while cAMP plays some role in the inhibition of mast cell mediator release, the demonstration that PGE<sub>2</sub> also closes K<sub>Ca</sub>3.1 supports the view that cAMP-independent, K<sub>Ca</sub>3.1-dependent mechanisms also contribute in part to EP<sub>2</sub>-dependent inhibition of HLMC mediator release.</p><p>In many diseases the recruitment of mast cells to key tissue structures appears critical for their pathophysiological effects <xref ref-type="bibr" rid="b4">4</xref>, <xref ref-type="bibr" rid="b26">26</xref>, <xref ref-type="bibr" rid="b27">27</xref>. For example, the contribution of mast cells to the disordered airway physiology of asthma is undoubtedly facilitated by their migration into the airway epithelium <xref ref-type="bibr" rid="b3">3</xref>, submucosal glands <xref ref-type="bibr" rid="b5">5</xref> and ASM <xref ref-type="bibr" rid="b4">4</xref>. Inhibition of their migration and subsequent microlocalisation within these structures might therefore offer a novel approach to therapy. Blockade of K<sub>Ca</sub>3.1 markedly inhibits HLMC migration in response to a number of diverse chemotactic stimuli including conditioned medium from activated asthmatic ASM <xref ref-type="bibr" rid="b6">6</xref>. The ability of PGE<sub>2</sub> to close K<sub>Ca</sub>3.1 suggested that it should also inhibit HLMC migration. However, its ability to inhibit HLMC migration in response to ASM-conditioned medium was variable and did not reach statistical significance. In contrast, the selective EP<sub>2</sub> receptor agonist butaprost, which was more potent at closing K<sub>Ca</sub>3.1 than PGE<sub>2</sub>, produced a marked and consistent inhibition of HLMC migration. PGE<sub>2</sub> was also chemotactic at high concentrations when used alone, but was more potent as a chemoattractant when EP<sub>2</sub> receptors were blocked. This indicates that there are competing pro-migratory and anti-migratory signals when PGE<sub>2</sub> is present, mediated by the EP<sub>2</sub> receptor (inhibitory) and most probably the EP<sub>3</sub> receptor (pro-migratory). These findings are in marked contrast to those in mouse bone marrow-derived mast cells in which PGE<sub>2</sub> in isolation is a potent chemoattractant. This chemotactic activity is mediated through the EP<sub>3</sub> receptor, and the lack of inhibition can be attributed to the absence of EP<sub>2</sub> receptors in mouse bone marrow-derived mast cells <xref ref-type="bibr" rid="b13">13</xref>. In human cord blood-derived mast cells, which express both EP<sub>2</sub> and EP<sub>3</sub> receptors, PGE<sub>2</sub> is not a chemoattractant <xref ref-type="bibr" rid="b13">13</xref>, compatible with an inhibitory role for the EP<sub>2</sub> receptor. In human lung therefore, PGE<sub>2</sub> is not likely to act as a HLMC chemoattractant, in keeping with its anti-inflammatory activities in this tissue <xref ref-type="bibr" rid="b18">18</xref>.</p><p>In humans PGE<sub>2</sub> inhibits the early and late asthmatic airway response to allergen challenge <xref ref-type="bibr" rid="b18">18</xref>. The ability of PGE<sub>2</sub> to close K<sub>Ca</sub>3.1 provides a mechanism through which it is able to achieve these effects. It will be of great interest to investigate whether PGE<sub>2</sub> has similar effects on lung T-cell K<sub>Ca</sub>3.1 function, cytokine secretion and migration, and whether it can inhibit K<sub>Ca</sub>3.1-dependent ASM proliferation <xref ref-type="bibr" rid="b28">28</xref>. Drugs that block K<sub>Ca</sub>3.1 are also in development as anti-inflammatory treatments <xref ref-type="bibr" rid="b29">29</xref>. Our demonstration that the EP<sub>2</sub> receptor closes K<sub>Ca</sub>3.1 in HLMC provides further support for the development of specific EP<sub>2</sub> receptor agonists for the treatment of mast cell-mediated pulmonary disease.</p></sec><sec sec-type="materials|methods"><title>Materials and methods</title><sec><title>Reagents</title><p>We used the following reagents: SCF, IL-6 and IL-10 (R&#x00026;D, Abingdon, UK); goat polyclonal anti-human IgE, PGE<sub>2</sub>, AH6809, butaprost, PAF, LPA, UTP (Sigma, Poole, Dorset, UK); 17-phenyl trinor PGE<sub>2</sub> (Cayman Chemical Company, Ann Arbor, Michigan, US); mouse IgG<sub>1</sub> mAb YB5.B8 (anti-CD117) (Cambridge Bioscience, Cambridge, UK); sheep anti-mouse IgG<sub>1</sub> Dynabeads (Dynal, Wirral, UK); Dulbecco's Modified Essential Medium (DMEM)/glutamax/HEPES, antibiotic/antimycotic solution, MEM non-essential aminoacids, and fetal calf serum (Life Technologies, Paisley, Scotland, UK).</p></sec><sec><title>Human mast cell purification and culture</title><p>All human subjects gave written informed consent, and the study was approved by the Leicestershire Research Ethics Committee. HLMC were dispersed and purified from macroscopically normal lung (<italic>n</italic>=14 donors) obtained within 1 h of resection for lung cancer using immunomagnetic affinity selection as described previously <xref ref-type="bibr" rid="b30">30</xref>. Final mast cell purity determined by Kimura stain was &#x0003e;99% and viability determined by Trypan blue was &#x0003e;97%. HLMC were cultured in DMEM/glutamax/HEPES containing antibiotic/antimycotic solution, non-essential amino acids, 10% fetal calf serum, 100 ng/mL SCF, 50 ng/mL IL-6, and 10 ng/mL IL-10 for up to 10 wk as described previously <xref ref-type="bibr" rid="b8">8</xref>, <xref ref-type="bibr" rid="b31">31</xref>.</p></sec><sec><title>Electrophysiology</title><p>The whole-cell variant of the patch-clamp technique was used <xref ref-type="bibr" rid="b7">7</xref>, <xref ref-type="bibr" rid="b32">32</xref>. Patch pipettes were made from borosilicate fibre-containing glass (Clark Electromedical Instruments, Reading, UK), and their tips were heat polished, typically resulting in resistances of 4&#x02013;6 M&#x003a9;. The standard pipette solution contained (in mM) KCl, 140; MgCl<sub>2</sub>, 2; HEPES, 10; Na<sup>+</sup>-ATP, 2; GTP, 0.1 (pH 7.3). The standard external solution contained (in mM) NaCl, 140; KCl, 5, CaCl<sub>2</sub>, 2; MgCl<sub>2</sub>,1; HEPES, 10 (pH 7.3). For recording, mast cells were placed in 35-mm dishes containing standard external solution. Whole-cell currents were recorded using an Axoclamp 200A amplifier (Axon Instruments, Foster City, CA, USA), and currents were evoked by applying voltage commands to a range of potentials in 10 mV steps from a holding potential of &#x02212;20 mV. The currents were digitised (sampled at a frequency of 10 kHz), stored on computer, and subsequently analysed using pClamp software (Axon Instruments). Capacitance transients were minimised using the capacitance neutralisation circuits on the amplifier. Correction for series resistance was not routinely applied. Experiments were performed at 27&#x000b0;C, and the temperature controlled by a Peltier device. Experiments were performed with a perfusion system (Automate Scientific, San Francisco, CA) to allow solution changes, although drugs were added directly to the recording chamber.</p><p>PGE<sub>2</sub> was dissolved in ethanol to give a stock solution of 10<sup>&#x02212;2</sup> M. Thus, at the maximal concentration PGE<sub>2</sub> used (10<sup>&#x02212;5</sup> M), the concentration of ethanol in the recording chamber was 0.1%. This concentration of ethanol did not affect K<sub>Ca</sub>3.1 currents when tested in isolation.</p></sec><sec><title>HLMC chemotaxis</title><p>HLMC chemotaxis assays were performed using the Transwell system (BD Biosciences, Oxford, UK) with 24-well plates as described previously <xref ref-type="bibr" rid="b6">6</xref>, <xref ref-type="bibr" rid="b20">20</xref>. Conditioned medium from asthmatic ASM that had been activated with TNF&#x003b1;, IL-1&#x003b2; and IFN&#x003b3; was placed in the lower wells as described previously <xref ref-type="bibr" rid="b20">20</xref>, with appropriate cytokine containing medium in the negative control. PGE<sub>2</sub> was added to the bottom wells in the concentration range 10<sup>&#x02212;6</sup>&#x02013;10<sup>&#x02212;3</sup> M. A total of 1&#x000d7;10<sup>5</sup> HLMC in 100 &#x000b5;L were added to the top well. After incubating the cells for 3 h at 37&#x000b0;C, we counted the number of HLMC in the bottom well using Kimura stain in a haemocytometer. HLMC migration was calculated as the fold increase of migrated cells in the test wells compared with the negative control (no chemoattractant in the lower well) as described previously <xref ref-type="bibr" rid="b6">6</xref>, <xref ref-type="bibr" rid="b20">20</xref>.</p></sec><sec><title>Data presentation and statistical analysis</title><p>Data are expressed as mean&#x000b1;SEM. unless otherwise stated. Differences between groups of data were explored using Student's paired or unpaired <italic>t</italic>-test (two-tailed) as appropriate.</p></sec></sec></body><back><ack><p>Supported by the Wellcome Trust, grant number 076264.</p></ack><sec><title>Conflict of interest:</title><p>The authors declare no financial or commercial conflict of interest.</p></sec><ref-list><title>References</title><ref id="b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradding</surname><given-names>P</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name></person-group><article-title>Immunopathology and human mast cell cytokines</article-title><source>Crit. Rev. Oncol. Haematol.</source><year>1999</year><volume>31</volume><fpage>119</fpage><lpage>133</lpage></element-citation></ref><ref id="b2"><label>2</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Busse</surname><given-names>WW</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name></person-group><article-title>Mast cells in asthma</article-title><source>Asthma &#x00026; Rhinitis</source><year>2000</year><publisher-loc>Boston</publisher-loc><publisher-name>Blackwell Scientific Publications</publisher-name><fpage>319</fpage><lpage>338</lpage></element-citation></ref><ref id="b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradding</surname><given-names>P</given-names></name><name><surname>Roberts</surname><given-names>JA</given-names></name><name><surname>Britten</surname><given-names>KM</given-names></name><name><surname>Montefort</surname><given-names>S</given-names></name><name><surname>Djukanovic</surname><given-names>R</given-names></name><name><surname>Mueller</surname><given-names>R</given-names></name><name><surname>Heusser</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>1994</year><volume>10</volume><fpage>471</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">8179909</pub-id></element-citation></ref><ref id="b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name><name><surname>Symon</surname><given-names>FA</given-names></name><name><surname>Holgate</surname><given-names>ST</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name><name><surname>Pavord</surname><given-names>ID</given-names></name></person-group><article-title>Mast cell infiltration of airway smooth muscle in asthma</article-title><source>N. Engl. J. Med.</source><year>2002</year><volume>346</volume><fpage>1699</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">12037149</pub-id></element-citation></ref><ref id="b5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>NG</given-names></name><name><surname>Mutavdzic</surname><given-names>S</given-names></name><name><surname>James</surname><given-names>AL</given-names></name></person-group><article-title>Increased mast cells and neutrophils in submucosal mucous glands and mucus plugging in patients with asthma</article-title><source>Thorax</source><year>2002</year><volume>57</volume><fpage>677</fpage><lpage>682</lpage><pub-id pub-id-type="pmid">12149526</pub-id></element-citation></ref><ref id="b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cruse</surname><given-names>G</given-names></name><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>Functional KCa3.1 K+ channels are required for human lung mast cell migration</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>880</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">16809411</pub-id></element-citation></ref><ref id="b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Lawley</surname><given-names>WJ</given-names></name><name><surname>Conley</surname><given-names>EC</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>Resting and activation-dependent ion channels in human mast cells</article-title><source>J. Immunol.</source><year>2001</year><volume>167</volume><fpage>4261</fpage><lpage>4270</lpage><pub-id pub-id-type="pmid">11591748</pub-id></element-citation></ref><ref id="b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Berger</surname><given-names>P</given-names></name><name><surname>Cruse</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Bolton</surname><given-names>SJ</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>The K<sup>+</sup> channel IK<sub>Ca</sub>1 potentiates Ca<sup>2+</sup> influx and degranulation in human lung mast cells</article-title><source>J. Allergy Clin. Immunol.</source><year>2004</year><volume>114</volume><fpage>66</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">15241346</pub-id></element-citation></ref><ref id="b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Cruse</surname><given-names>G</given-names></name><name><surname>Lawley</surname><given-names>WJ</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>Beta2-adrenoceptor regulation of the K+ channel IK<sub>Ca</sub>1 in human mast cells</article-title><source>FASEB J</source><year>2005</year><volume>19</volume><fpage>1006</fpage><lpage>1008</lpage><pub-id pub-id-type="pmid">15817638</pub-id></element-citation></ref><ref id="b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Cruse</surname><given-names>G</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>Adenosine closes the K+ channel KCa3.1 in human lung mast cells and inhibits their migration via the adenosine A<sub>2A</sub> receptor</article-title><source>Eur. J. Immunol.</source><year>2007</year><volume>37</volume><fpage>1653</fpage><lpage>1662</lpage><pub-id pub-id-type="pmid">17474152</pub-id></element-citation></ref><ref id="b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugimoto</surname><given-names>Y</given-names></name><name><surname>Narumiya</surname><given-names>S</given-names></name></person-group><article-title>Prostaglandin E receptors</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>11613</fpage><lpage>11617</lpage><pub-id pub-id-type="pmid">17329241</pub-id></element-citation></ref><ref id="b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>M</given-names></name><name><surname>Solle</surname><given-names>M</given-names></name><name><surname>Audoly</surname><given-names>LP</given-names></name><name><surname>Tilley</surname><given-names>SL</given-names></name><name><surname>Stock</surname><given-names>JL</given-names></name><name><surname>McNeish</surname><given-names>JD</given-names></name><name><surname>Coffman</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production</article-title><source>J. Immunol.</source><year>2002</year><volume>169</volume><fpage>4586</fpage><lpage>4593</lpage><pub-id pub-id-type="pmid">12370397</pub-id></element-citation></ref><ref id="b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weller</surname><given-names>CL</given-names></name><name><surname>Collington</surname><given-names>SJ</given-names></name><name><surname>Hartnell</surname><given-names>A</given-names></name><name><surname>Conroy</surname><given-names>DM</given-names></name><name><surname>Kaise</surname><given-names>T</given-names></name><name><surname>Barker</surname><given-names>JE</given-names></name><name><surname>Wilson</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Chemotactic action of prostaglandin E2 on mouse mast cells acting via the PGE2 receptor 3</article-title><source>Proc. Nat. Acad. Sci.</source><year>2007</year><volume>104</volume><fpage>11712</fpage><lpage>11717</lpage><pub-id pub-id-type="pmid">17606905</pub-id></element-citation></ref><ref id="b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>C</given-names></name><name><surname>Beller</surname><given-names>EM</given-names></name><name><surname>Bagga</surname><given-names>S</given-names></name><name><surname>Boyce</surname><given-names>JA</given-names></name></person-group><article-title>Human mast cells express multiple EP receptors for prostaglandin E2 that differentially modulate activation responses</article-title><source>Blood</source><year>2006</year><volume>107</volume><fpage>3243</fpage><lpage>3250</lpage><pub-id pub-id-type="pmid">16357326</pub-id></element-citation></ref><ref id="b15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peachell</surname><given-names>PT</given-names></name><name><surname>MacGlashan</surname><given-names>DW</given-names><suffix>Jr.</suffix></name><name><surname>Lichtenstein</surname><given-names>LM</given-names></name><name><surname>Schleimer</surname><given-names>RP</given-names></name></person-group><article-title>Regulation of human basophil and lung mast cell function by cyclic adenosine monophosphate</article-title><source>J. Immunol.</source><year>1988</year><volume>140</volume><fpage>571</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">2447182</pub-id></element-citation></ref><ref id="b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kay</surname><given-names>LJ</given-names></name><name><surname>Yeo</surname><given-names>WW</given-names></name><name><surname>Peachell</surname><given-names>PT</given-names></name></person-group><article-title>Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation</article-title><source>Br. J. Pharmacol.</source><year>2006</year><volume>147</volume><fpage>707</fpage><lpage>713</lpage><pub-id pub-id-type="pmid">16432506</pub-id></element-citation></ref><ref id="b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>SP</given-names></name><name><surname>Schulman</surname><given-names>ES</given-names></name><name><surname>Schleimer</surname><given-names>RP</given-names></name><name><surname>MacGlashan</surname><given-names>DW</given-names><suffix>Jr.</suffix></name><name><surname>Newball</surname><given-names>HH</given-names></name><name><surname>Lichtenstein</surname><given-names>LM</given-names></name></person-group><article-title>Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments</article-title><source>Am. Rev. Respir. Dis.</source><year>1982</year><volume>126</volume><fpage>1034</fpage><lpage>1039</lpage><pub-id pub-id-type="pmid">6185023</pub-id></element-citation></ref><ref id="b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavord</surname><given-names>ID</given-names></name><name><surname>Wong</surname><given-names>CS</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Tattersfield</surname><given-names>AE</given-names></name></person-group><article-title>Effect of inhaled prostaglandin E2 on allergen-induced asthma</article-title><source>Am. Rev. Respir. Dis.</source><year>1993</year><volume>148</volume><fpage>87</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">8317820</pub-id></element-citation></ref><ref id="b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>KA</given-names></name><name><surname>Schroder</surname><given-names>RL</given-names></name><name><surname>Skaaning-Jensen</surname><given-names>B</given-names></name><name><surname>Strobaek</surname><given-names>D</given-names></name><name><surname>Olesen</surname><given-names>SP</given-names></name><name><surname>Christophersen</surname><given-names>P</given-names></name></person-group><article-title>Activation of the human intermediate-conductance Ca(2+)-activated K(+) channel by 1-ethyl-2-benzimidazolinone is strongly Ca(2+)-dependent</article-title><source>Biochim. Biophys. Acta</source><year>1999</year><volume>1420</volume><fpage>231</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">10446306</pub-id></element-citation></ref><ref id="b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Ammit</surname><given-names>AJ</given-names></name><name><surname>Kaur</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>JL</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2005</year><volume>171</volume><fpage>1103</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">15879427</pub-id></element-citation></ref><ref id="b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tedford</surname><given-names>HW</given-names></name><name><surname>Zamponi</surname><given-names>GW</given-names></name></person-group><article-title>Direct G protein modulation of Cav2 calcium channels</article-title><source>Pharmacol. Rev.</source><year>2006</year><volume>58</volume><fpage>837</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">17132857</pub-id></element-citation></ref><ref id="b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kume</surname><given-names>H</given-names></name><name><surname>Graziano</surname><given-names>MP</given-names></name><name><surname>Kotlikoff</surname><given-names>MI</given-names></name></person-group><article-title>Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>1992</year><volume>89</volume><fpage>11051</fpage><lpage>11055</lpage><pub-id pub-id-type="pmid">1438313</pub-id></element-citation></ref><ref id="b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>SM</given-names></name><name><surname>Cui</surname><given-names>J</given-names></name><name><surname>Marx</surname><given-names>SO</given-names></name></person-group><article-title>Assembly of a Ca2+-dependent BK channel signaling complex by binding to beta2 adrenergic receptor</article-title><source>EMBO J.</source><year>2004</year><volume>23</volume><fpage>2196</fpage><lpage>2205</lpage><pub-id pub-id-type="pmid">15141163</pub-id></element-citation></ref><ref id="b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weston</surname><given-names>MC</given-names></name><name><surname>Peachell</surname><given-names>PT</given-names></name></person-group><article-title>Regulation of human mast cell and basophil function by cAMP</article-title><source>Gen. Pharmacol.</source><year>1998</year><volume>31</volume><fpage>715</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">9809467</pub-id></element-citation></ref><ref id="b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kume</surname><given-names>H</given-names></name><name><surname>Hall</surname><given-names>IP</given-names></name><name><surname>Washabau</surname><given-names>RJ</given-names></name><name><surname>Takagi</surname><given-names>K</given-names></name><name><surname>Kotlikoff</surname><given-names>MI</given-names></name></person-group><article-title>Beta-adrenergic agonists regulate KCa channels in airway smooth muscle by cAMP-dependent and -independent mechanisms</article-title><source>J. Clin. Invest.</source><year>1994</year><volume>93</volume><fpage>371</fpage><lpage>379</lpage><pub-id pub-id-type="pmid">7904270</pub-id></element-citation></ref><ref id="b26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>King</surname><given-names>TEJ</given-names></name><name><surname>Tinkle</surname><given-names>SS</given-names></name><name><surname>Dockstader</surname><given-names>K</given-names></name><name><surname>Newman</surname><given-names>LS</given-names></name></person-group><article-title>Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders</article-title><source>Am. J. Pathol.</source><year>1996</year><volume>149</volume><fpage>2037</fpage><lpage>2054</lpage><pub-id pub-id-type="pmid">8952537</pub-id></element-citation></ref><ref id="b27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotis-Graham</surname><given-names>I</given-names></name><name><surname>McNeil</surname><given-names>HP</given-names></name></person-group><article-title>Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression</article-title><source>Arthritis Rheum.</source><year>1997</year><volume>40</volume><fpage>479</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">9082936</pub-id></element-citation></ref><ref id="b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>MC</given-names></name><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Harris</surname><given-names>T</given-names></name><name><surname>Cruse</surname><given-names>G</given-names></name><name><surname>Schuliga</surname><given-names>M</given-names></name><name><surname>Brightling</surname><given-names>CE</given-names></name><name><surname>Neylon</surname><given-names>CB</given-names></name><etal/></person-group><article-title>K<sub>Ca</sub>3.1 Ca<sup>2+</sup> activated K<sup>+</sup> channels regulate human airway smooth muscle proliferation</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2007</year><volume>37</volume><fpage>525</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">17585114</pub-id></element-citation></ref><ref id="b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandy</surname><given-names>KG</given-names></name><name><surname>Wulff</surname><given-names>H</given-names></name><name><surname>Beeton</surname><given-names>C</given-names></name><name><surname>Pennington</surname><given-names>M</given-names></name><name><surname>Gutman</surname><given-names>GA</given-names></name><name><surname>Cahalan</surname><given-names>MD</given-names></name></person-group><article-title>K+ channels as targets for specific immunomodulation</article-title><source>Trends Pharmacol. Sci.</source><year>2004</year><volume>25</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">15120495</pub-id></element-citation></ref><ref id="b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanmugalingam</surname><given-names>D</given-names></name><name><surname>Wardlaw</surname><given-names>AJ</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>Adhesion of human lung mast cells to bronchial epithelium: evidence for a novel carbohydrate-mediated mechanism</article-title><source>J. Leuk. Biol.</source><year>2000</year><volume>68</volume><fpage>38</fpage><lpage>46</lpage></element-citation></ref><ref id="b31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Lawley</surname><given-names>WJ</given-names></name><name><surname>Kaur</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Bradding</surname><given-names>P</given-names></name></person-group><article-title>Inhibition of human mast cell proliferation and survival by tamoxifen in association with ion channel modulation</article-title><source>J. Allergy Clin. Immunol.</source><year>2003</year><volume>112</volume><fpage>970</fpage><lpage>977</lpage></element-citation></ref><ref id="b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamill</surname><given-names>OP</given-names></name><name><surname>Marty</surname><given-names>A</given-names></name><name><surname>Neher</surname><given-names>E</given-names></name><name><surname>Sakmann</surname><given-names>B</given-names></name><name><surname>Sigworth</surname><given-names>FJ</given-names></name></person-group><article-title>Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches</article-title><source>Pflugers Archiv.&#x02014;Eur. J. Physiol.</source><year>1981</year><volume>391</volume><fpage>85</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">6270629</pub-id></element-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>ASM</term><def><p>airway smooth muscle</p></def></def-item><def-item><term>EP</term><def><p>E prostanoid receptor</p></def></def-item><def-item><term>1-EBIO</term><def><p>1-ethyl-2-benzimidazolinone</p></def></def-item><def-item><term>GPCR</term><def><p>G protein-coupled receptor</p></def></def-item><def-item><term>HLMC</term><def><p>human lung mast cell</p></def></def-item><def-item><term>LPA</term><def><p>lysophosphatidic acid</p></def></def-item><def-item><term>PAF</term><def><p>platelet activating factor</p></def></def-item><def-item><term>PG</term><def><p>prostaglandin</p></def></def-item></def-list></glossary></back></article>